Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 97 companies made new 52-week lows.
Goldman Sachs Maintains Buy on Kronos Bio, Lowers Price Target to $14
Goldman Sachs analyst Salveen Richter maintains Kronos Bio (NASDAQ:KRON) with a Buy and lowers the price target from $25 to $14.
Benzinga’s Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades
For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low of $2.89. Moreover, at the end of the last trading period, the closing price was at $4.26.
Berenberg Initiates Coverage On Kronos Bio with Buy Rating, Announces Price Target of $12
Berenberg analyst Zhiqiang Shu initiates coverage on Kronos Bio (NASDAQ:KRON) with a Buy rating and announces Price Target of $12.
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery…
Kronos Bio Shares Fall After Initial-Stage Blood Cancer Study Takes-off
Kronos Bio (NASDAQ: KRON) has initiated patient dosing in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).